Dental Professionals

Ready, Set, Reverse.

It's a whole new direction in distinguishing your practice. And doctors all over the U.S. are introducing their patients to the reality of accelerating the reversal of lingering numbness with OraVerse. It's the first and only local anesthesia reversal agent that allows you to bring patients back to normal sensation and function about twice as fast.* In fact, in clinical trials, patients were more quickly able to:

  • Smile
  • Speak
  • Drink normally
  • Avoid drooling


"I don't just get numb, I stay numb for hours. That means half the day is gone before I can feel my lips and tongue again."
        -- Connie L., dental patient, Chicago, Illinois


Market research shows 87% of patients may be interested in receiving a product like OraVerse1. Respondents were aware that a second injection was required and that there may be an extra charge.


OraVerse is indicated for use in adults and children 6 years of age or older and weighing at least 33 lbs.

The most common adverse events with OraVerse that were greater than the control group were injection site pain (5% vs. 4%) and bradycardia (2% vs. 0.3%).

"OraVerse is a great benefit for my patients, and I'm excited to offer it to them."
        -- Dr Lawrence Addleson
           Past President, American Academy of Cosmetic Dentistry

Important Safety Information

Following parenteral use of phentolamine at doses between 5 and 15 times higher than the recommended dose of OraVerse (phentolamine mesylate), myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia, bradycardia, and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents. See full prescribing information for details.



1. Novalar Research Summary (n=253), Strategic Dental Marketing, Inc., April 2004.

* In randomized, controlled clinical trials, median time to recovery of lip sensation was reduced by 85 minutes (55%) for lower lip and by 83 minutes (62%) for upper lip compared to control. Median time to recovery of normal function was reduced by 60 minutes (50%) in the mandible (lower jaw) and by 45 minutes (43%) in the maxilla (upper jaw) compared with control.